1672 — Ascletis Pharma Income Statement
0.000.00%
- HK$1.09bn
- -HK$1.37bn
- CNY56.60m
- 31
- 25
- 17
- 10
Annual income statement for Ascletis Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 173 | 35 | 76.9 | 54.1 | 56.6 |
Cost of Revenue | |||||
Gross Profit | 124 | -23.5 | 39.2 | -24.7 | 26 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 258 | 230 | 258 | 346 | 181 |
Operating Profit | -84.3 | -195 | -181 | -292 | -124 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -96 | -209 | -199 | -315 | -145 |
Provision for Income Taxes | |||||
Net Income After Taxes | -96 | -209 | -199 | -315 | -145 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -96 | -209 | -199 | -315 | -145 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -96 | -209 | -199 | -315 | -145 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.09 | -0.196 | -0.181 | -0.239 | -0.136 |